Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk COVID-19 patients in north west London: a retrospective cohort study.
Drysdale M, Galimov ER, Yarwood MJ, Patel V, Levick B, Gibbons DC, Watkins JD, Young S, Pierce BF, Lloyd EJ, Kerr W, Birch HJ, Kamalati T, Brett SJ. Drysdale M, et al. Among authors: birch hj. BMJ Open Respir Res. 2024 Apr 4;11(1):e002238. doi: 10.1136/bmjresp-2023-002238. BMJ Open Respir Res. 2024. PMID: 38575338 Free PMC article.
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C).
Bell CF, Bobbili P, Desai R, Gibbons DC, Drysdale M, DerSarkissian M, Patel V, Birch HJ, Lloyd EJ, Zhang A, Duh MS; N3C consortium. Bell CF, et al. Among authors: birch hj. Clin Drug Investig. 2024 Mar;44(3):183-198. doi: 10.1007/s40261-024-01344-4. Epub 2024 Feb 20. Clin Drug Investig. 2024. PMID: 38379107 Free PMC article.
Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England: a retrospective cohort study.
Patel V, Yarwood MJ, Levick B, Gibbons DC, Drysdale M, Kerr W, Watkins JD, Young S, Pierce BF, Lloyd EJ, Birch HJ, Kamalati T, Brett SJ. Patel V, et al. Among authors: birch hj. Curr Med Res Opin. 2024 Aug;40(8):1323-1334. doi: 10.1080/03007995.2024.2376144. Epub 2024 Jul 8. Curr Med Res Opin. 2024. PMID: 38975862
Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records.
Bell CF, Gibbons DC, Drysdale M, Birch HJ, Lloyd EJ, Patel V, Carpenter C, Carlson K, Calay ES, Puranik A, Wagner TE, O'Horo JC, Razonable RR. Bell CF, et al. Among authors: birch hj. PLoS One. 2024 Jul 16;19(7):e0304822. doi: 10.1371/journal.pone.0304822. eCollection 2024. PLoS One. 2024. PMID: 39012863 Free PMC article.
Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19.
Satram S, Ghafoori P, Reyes CM, Keeley TJH, Birch HJ, Brintziki D, Aldinger M, Alexander E, Lopuski A, Sarkis EH, Gupta A, Shapiro AE, Powers JH 3rd. Satram S, et al. Among authors: birch hj. J Patient Rep Outcomes. 2023 Sep 13;7(1):92. doi: 10.1186/s41687-023-00621-8. J Patient Rep Outcomes. 2023. PMID: 37702920 Free PMC article. Clinical Trial.
Content validity and psychometric properties of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus©) instrument in patients with COVID-19.
Keeley TJH, Satram S, Ghafoori P, Reyes C, Birch HJ, Raymond K, Gelhorn HL, Kosinski M, Saucier CD, Mitchell Foster A, Lopuski A, Powers JH 3rd. Keeley TJH, et al. Among authors: birch hj. Qual Life Res. 2023 Jun;32(6):1645-1657. doi: 10.1007/s11136-022-03336-3. Epub 2023 Jan 27. Qual Life Res. 2023. PMID: 36703019 Free PMC article.
11 results